Wang Sheng-Min, Kang Dong Woo, Um Yoo Hyun, Kim Sunghwan, Lee Chang Uk, Scheltens Philip, Lim Hyun Kook
Department of Psychiatry, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-Ro, Yeongdeungpo-Gu, Seoul, 07345, South Korea.
Department of Psychiatry, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, 06591, South Korea.
Alzheimers Res Ther. 2024 Mar 11;16(1):55. doi: 10.1186/s13195-024-01400-3.
Multimer detection system-oligomeric amyloid-β (MDS-OAβ) is a measure of plasma OAβ, which is associated with Alzheimer's disease (AD) pathology. However, the relationship between MDS-OAβ and disease severity of AD is not clear. We aimed to investigate MDS-OAβ levels in different stages of AD and analyze the association between MDS-OAβ and cerebral Aβ deposition, cognitive function, and cortical thickness in subjects within the AD continuum.
In this cross-sectional study, we analyzed a total 126 participants who underwent plasma MDS-OAβ, structural magnetic resonance image of brain, and neurocognitive measures using Korean version of the Consortium to Establish a Registry for Alzheimer's Disease, and cerebral Aβ deposition or amyloid positron emission tomography (A-PET) assessed by [F] flutemetamol PET. Subjects were divided into 4 groups: N = 39 for normal control (NC), N = 31 for A-PET-negative mild cognitive impairment (MCI) patients, N = 30 for A-PET-positive MCI patients, and N = 22 for AD dementia patients. The severity of cerebral Aβ deposition was expressed as standard uptake value ratio (SUVR).
Compared to the NC (0.803 ± 0.27), MDS-OAβ level was higher in the A-PET-negative MCI group (0.946 ± 0.137) and highest in the A-PET-positive MCI group (1.07 ± 0.17). MDS-OAβ level in the AD dementia group was higher than in the NC, but it fell to that of the A-PET-negative MCI group level (0.958 ± 0.103). There were negative associations between MDS-OAβ and cognitive function and both global and regional cerebral Aβ deposition (SUVR). Cortical thickness of the left fusiform gyrus showed a negative association with MDS-OAβ when we excluded the AD dementia group.
These findings suggest that MDS-OAβ is not only associated with neurocognitive staging, but also with cerebral Aβ burden in patients along the AD continuum.
多聚体检测系统 - 寡聚淀粉样β蛋白（MDS - OAβ）是血浆中OAβ的一种检测指标，其与阿尔茨海默病（AD）病理相关。然而，MDS - OAβ与AD疾病严重程度之间的关系尚不清楚。我们旨在研究AD不同阶段的MDS - OAβ水平，并分析MDS - OAβ与AD连续体中受试者脑Aβ沉积、认知功能和皮质厚度之间的关联。
在这项横断面研究中，我们分析了总共126名参与者，他们接受了血浆MDS - OAβ检测、脑部结构磁共振成像以及使用韩国版阿尔茨海默病注册协会量表进行的神经认知测量，并且通过[F]氟代脱氧葡萄糖正电子发射断层显像（A - PET）评估了脑Aβ沉积情况。受试者被分为4组：正常对照组（NC，n = 39）、A - PET阴性轻度认知障碍（MCI）患者组（n = 31）、A - PET阳性MCI患者组（n = 30）和AD痴呆患者组（n = 22）。脑Aβ沉积的严重程度用标准摄取值比率（SUVR）表示。
与NC组（0.803 ± 0.27）相比，A - PET阴性MCI组的MDS - OAβ水平更高（0.946 ± 0.137），而A - PET阳性MCI组最高（1. .07 ± 0.17）。AD痴呆组的MDS - OAβ水平高于NC组，但降至A - PET阴性MCI组的水平（0.958 ± 0.103）。MDS - OAβ与认知功能以及全脑和局部脑Aβ沉积（SUVR）之间存在负相关。当我们排除AD痴呆组时，左侧梭状回的皮质厚度与MDS - OAβ呈负相关。
这些发现表明，MDS - OAβ不仅与神经认知分期相关，而且与AD连续体中患者的脑Aβ负荷相关。
